Editor's Corner

  • Luxembourg's Eurofins rides JV diagnostics wave with Emory University deal

    It has been a busy week for joint ventures in the diagnostics industry, with Qiagen teaming up with German outfit Biotype Diagnostics to create a new business geared toward companion diagnostic tests. Now, Luxembourg diagnostics company Eurofins is hopping on the JV bandwagon, shelling out $40 million to take a deeper dive into genetics with Emory University's Genetics Laboratory (EGL). Read more >>

Allscripts takes $200M stake in NantHealth to strengthen personalized medicine alliance

Electronic medical records company Allscripts took a $200 million (or 10%) stake in drug discovery company NantHealth to strengthen their alliance focused on personalized medicine in the cancer treatment arena.

Cinven snatches up Synlab for $1.96B to beef up in diagnostics

European private equity firm Cinven is snatching up German medical lab operator Synlab for €1.75 billion ($1.96 billion), continuing its dealmaking streak weeks after it announced it would shell out $1.3 billion for French diagnostics outfit Labco.

Google and the Broad Institute join forces for genomic data sharing

Google is teaming up with The Broad Institute of MIT and Harvard to create new ways of sharing genomic data and reduce barriers associated with storing and processing genetic information.

NIH provides Great Basin Scientific and BYU $5M+ to develop rapid test for CRE

The National Institutes of Health has awarded more than $5 million over 5 years to diagnostics company Great Basin Scientific and Brigham Young University to develop a rapid molecular diagnostic test from whole blood for carbapenem-resistant Enterobacteriaceae (CRE).

Illumina unveils plans for new European HQ and science center

Illumina is laying out plans for expansion, signing a 20-year lease on a 155,000-square-foot facility in Cambridge, England.


From Our Sister Sites


PPD, angling to stand out among CROs running pediatric trials, has cemented a network of 8 global sites to accelerate the process of starting studies on kids.


Switzerland-based Actelion is jumping into the vaccines industry by creating Vaxxilon, a startup that will focus on synthetic carbohydrate vaccines. It has licensed exclusive rights to multiple preclinical vaccines and other technologies from the Max Planck Society and will invest up to €30 million ($33 million), which will come in tranches over three to four years.